Last updated: March 3, 2026
What Is NDC 71205-0936?
NDC 71205-0936 is a prescription drug identified by the National Drug Code (NDC). It corresponds to [specific drug name], approved by the FDA for [indication]. The drug is manufactured by [manufacturer], with an approval date of [approval date]. It is available in [formulation], with a typical dosage of [dosage].
Market Size and Sales Volume
The market size for this drug primarily depends on the prevalence of the condition it treats and competitive dynamics.
| Metric |
Data |
| Estimated US patient population |
[Number] patients (source: [institution]) |
| Annual treatment rate |
[Number] patients (calculated based on prevalence) |
| Market penetration rate |
[Percentage]% (current estimate) |
| Total potential market revenue |
$[value] billion (based on average treatment cost) |
The annual treatment cost per patient ranges between $[Lower Range] and $[Upper Range]. Current sales for NDC 71205-0936 are approximately $[value] million, representing [percentage]% of the total market for the therapy class.
Competitive Landscape
The drug faces competition from [number] alternative medications, including branded and generic options:
- Branded drugs: [Names, market share percentages]
- Generic equivalents: [Names, market share percentages]
Market share distribution indicates NDC 71205-0936 holds approximately [percentage]% of the treatment niche, with room for growth as generics gain approval.
Regulatory and Reimbursement Environment
Reimbursement policies significantly impact the drug's market penetration. Medicare, Medicaid, and private insurers reimburse based on negotiated rates, influencing patient access and prescriber adoption. Price controls and formulary placements are under scrutiny, with recent policies favoring cap on out-of-pocket costs and encouraging generic substitution.
Price Trends and Projections
Historical Price Data (U.S. Market)
| Year |
Average Wholesale Price (AWP) |
List Price per Unit |
Sales Revenue |
| 2020 |
$[value] |
$[value] |
$[value] M |
| 2021 |
$[value] |
$[value] |
$[value] M |
| 2022 |
$[value] |
$[value] |
$[value] M |
Price Drivers
- Increased competition prompts a price decline of approximately [percentage]% over the next 12 months.
- The entry of generics is expected to reduce price by an additional [percentage]%, potentially lowering the average unit price to $[projected value].
- Changes in reimbursement policies could influence pricing strategies, with manufacturers potentially offering rebates or discounts to maintain market share.
Future Price Projections (Next 5 Years)
| Year |
Projected Average Price |
Factors Influencing Price |
| 2023 |
$[value] |
Patent expiration, generic entry, policy adjustments |
| 2024 |
$[value] |
Increased market competition |
| 2025 |
$[value] |
Expansion into new indications |
| 2026 |
$[value] |
Potential drug formulary restrictions |
| 2027 |
$[value] |
Possible price stabilization or discounts |
In the absence of new formulation or indication approvals, prices are projected to decline by [percentage]% annually, stabilizing by 2027.
Market Growth Outlook
The compound annual growth rate (CAGR) for the drug’s sales is projected at [percentage]% over the next five years, driven by increased brand awareness, expanded indications, and broader payer coverage. The growth rate could be offset by generic competition and headline reforms.
Key Risks and Opportunities
-
Risks
- Patent expiry in [year], allowing generic competition
- Reimbursement policy reforms reducing profitability
- Entry of new treatments with superior efficacy or safety profiles
-
Opportunities
- Expanding indications to increase patient population
- Launching combination therapies to address unmet needs
- Strategic pricing negotiations with payers
Summary
NDC 71205-0936 operates in a competitive market with an estimated current revenue of $[value] million. Price reductions are anticipated as generics enter the market, with a projected decline of around [percentage]% over the next five years. Market growth will depend on regulatory developments and the drug’s ability to expand its clinical use.
Key Takeaways
- The drug’s market size is constrained by current competition and reimbursement policies.
- Prices are expected to decline due to patent expiration and generic entry.
- The product has growth potential through indications expansion and price negotiations.
- Competition and policy shifts present ongoing risks.
- Overall market revenue is projected to decrease over the next five years, aligning with falling prices.
FAQs
Q1: When does patent expiration for NDC 71205-0936 occur?
A1: The patent is set to expire in [year], after which generic competition is expected to increase.
Q2: What are the primary competitors?
A2: Key competitors include [drug names], accounting for [market share]% of the therapeutic class.
Q3: How does reimbursement impact pricing?
A3: Reimbursement rates influence the net price and patient access, often leading manufacturers to offer discounts or rebates.
Q4: What factors could accelerate price declines?
A4: Introduction of bioequivalent generics, regulatory changes, or policy reforms favoring cost containment.
Q5: Are there expansion opportunities for this drug?
A5: Yes, potential exists for expanding indications, which could bolster sales despite pricing pressures.
References
[1] FDA. (2023). Approved drug products: NDC 71205-0936. U.S. Food and Drug Administration.
[2] IMS Health. (2022). U.S. pharmacy-based clinical drug market data.
[3] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies and rate guides.
[4] IQVIA. (2022). Global Medicine Market Reports.
[5] EvaluatePharma. (2022). World Preview 2022, Outlook to 2027.
